Search company, investor...

Predict your next investment

Holding Company
FINANCE | Investment Firms & Funds
novoholdings.dk

Investments

262

Portfolio Exits

59

Partners & Customers

2

Service Providers

3

About Novo Holdings

Novo Holdings is the holding company of the Novo Group and manages the investment assets of the Novo Nordisk Foundation. It invests in life science companies at all stages of development and in a broad portfolio of equity and fixed-income securities. Novo Holdings was formerly known as Novo. The company was founded in 1999 and is based in Hellerup, Denmark.

Headquarters Location

Tuborg Havnevej 19

Hellerup, 2900,

Denmark

+45 3527 6500

Want to inform investors similar to Novo Holdings about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Novo Holdings News

Avalyn Raises $175 Million in Series C Financing

Sep 29, 2023

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, announced the closing of an oversubscribed $175 million Series C financing. The Series C financing was co-led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, which were joined by new investors, Vida Ventures, Wellington Management, Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates, Inc., Surveyor Capital (a Citadel Company), Catalio Capital Management, and Piper Heartland. Current investors, including Novo Holdings A/S, Norwest Venture Partners, F-Prime Capital, Pivotal bioVenture Partners, and RiverVest Venture Partners, also participated. In conjunction with the financing, Gianna Hoffman-Luca, Ph.D., of Perceptive Xontogeny Venture Funds, and Jill Carroll of SR One, joined Avalyn's Board of Directors. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

Novo Holdings Investments

262 Investments

Novo Holdings has made 262 investments. Their latest investment was in Avalyn as part of their Series C on September 9, 2023.

CBI Logo

Novo Holdings Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/27/2023

Series C

Avalyn

$175M

No

2

9/19/2023

Unattributed VC

HPNow

$14.94M

Yes

2

8/8/2023

Series A

Bactolife

$33M

Yes

2

8/7/2023

PIPE - II

Subscribe to see more

$99M

Subscribe to see more

10

7/28/2023

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/27/2023

9/19/2023

8/8/2023

8/7/2023

7/28/2023

Round

Series C

Unattributed VC

Series A

PIPE - II

Series D

Company

Avalyn

HPNow

Bactolife

Subscribe to see more

Subscribe to see more

Amount

$175M

$14.94M

$33M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

2

10

10

Novo Holdings Portfolio Exits

59 Portfolio Exits

Novo Holdings has 59 portfolio exits. Their latest portfolio exit was Altasciences Clinical Research on September 21, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/21/2023

Divestiture

$99M

2

2/9/2023

Reverse Merger

$99M

4

12/29/2022

Reverse Merger

$99M

5

12/12/2022

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

9/28/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/21/2023

2/9/2023

12/29/2022

12/12/2022

9/28/2022

Exit

Divestiture

Reverse Merger

Reverse Merger

Acq - Pending

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

4

5

10

10

Novo Holdings Acquisitions

13 Acquisitions

Novo Holdings acquired 13 companies. Their latest acquisition was Paratek Pharmaceuticals on September 20, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/20/2023

Debt

$99M

$129.3M

Take Private

10

6/21/2023

$99M

Acquired

10

9/23/2022

Other

$99M

Acquired

1

1/4/2022

Subscribe to see more

$99M

Subscribe to see more

10

1/3/2022

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/20/2023

6/21/2023

9/23/2022

1/4/2022

1/3/2022

Investment Stage

Debt

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$129.3M

Note

Take Private

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

10

10

1

10

10

Novo Holdings Partners & Customers

2 Partners and customers

Novo Holdings has 2 strategic partners and customers. Novo Holdings recently partnered with Industriens Pension, Urban Partners, and DSB Ejendomme on February 2, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

2/7/2023

Partner

Denmark

Novo Holdings · Four partners agree to jointly redevelop Jernbanebyen in Copenhagen

DSB , NREP , Industriens Pension and Novo Holdings have entered into a joint venture agreement to redevelop Jernbanebyen in Copenhagen .

2

11/19/2019

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

2/7/2023

11/19/2019

Type

Partner

Partner

Business Partner

Country

Denmark

United States

News Snippet

Novo Holdings · Four partners agree to jointly redevelop Jernbanebyen in Copenhagen

DSB , NREP , Industriens Pension and Novo Holdings have entered into a joint venture agreement to redevelop Jernbanebyen in Copenhagen .

Subscribe to see more

Subscribe to see more

Sources

2

10

Novo Holdings Service Providers

5 Service Providers

Novo Holdings has 5 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired - II

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acquired - II

Subscribe to see more

Subscribe to see more

Provider Type

Counsel

Subscribe to see more

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Novo Holdings Team

16 Team Members

Novo Holdings has 16 team members, including current Chief Executive Officer, Kasim Kutay.

Name

Work History

Title

Status

Kasim Kutay

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Kasim Kutay

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Novo Holdings to Competitors

Alexandra Instituttet Logo
Alexandra Instituttet

Alexandra Instituttet is an information technology consultant and developer. It provides artificial intelligence, digital green transition, cyber security, digital health, and more. It was founded in 1999 and is based in Aarhus, Denmark.

G
GI Innovation

GI Innovation is a bio-venture company that explores the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.

L
Luminary Therapeutics

Luminary is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with cell engineering to overcome antigen escape and T-cell dysfunction. Its therapeutic solutions include BAFF CAR-T, Universal Receptor, and a non-viral allogeneic platform. The company was founded in 2019 and is based in Minneapolis, Minnesota.

7
7 Hills Pharma

7 Hills Pharma develops an immunotherapy platform to boost the efficiency of immune checkpoint inhibitors and vaccines against infectious diseases. It boosts the anticancer activity of multiple novel cell-based immunotherapies, giving consumers access to medicines that boost the potency of novel immuno-oncology medications and vaccinations for infectious diseases. The company was founded in 2015 and is based in Houston, Texas.

H
Healios

Healios provides patients and doctors with mobile health platforms and Digital Biomarkers to improve patient diagnosis and treatment, research and clinical practice. Healios was founded in 2012 and is based in Basel, Switzerland.

T
Theracell Advanced Biotechnology

Theracell Advanced Biotechnology provides personalized and precision medicine, enabling individualized treatment with improved outcome. It offers advanced therapy medicinal products (ATMP), which are comprised of gene therapy, somatic cell therapy, and tissue engineered products. Based on viable cells or tissues, their pharmacological, immunologic or metabolic action should be considered as the principal mode of action. The company's therapeutic portfolio spans the areas of orthopedics, dermatology, nephrology, immuno-oncology, and tissue repair and regeneration. Through strategic partnerships Theracell Advanced Biotechnology participates in the global vision of the realization of personalized medicine tailored to individual patient needs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.